Esophageal Cancer, Gastric Cancer, Hypoxia
Conditions
Keywords
Obese Patients, The COMBO Endoscopy Oropharyngeal Airway, Hypoxia, Sedation, Gastrointestinal Endoscopy
Brief summary
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing gastrointestinal endoscopy with propofol. This is particularly true for obese patients, who have a higher incidence of hypoxia. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy and safety of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in obese patients undergoing gastrointestinal endoscopy under sedation.
Interventions
DEVICEthe COMBO Endoscopy Oropharyngeal Airway Group
Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
DEVICERegular Nasal Cannula
Using regular nasal cannula for oxygenation.
Sponsors
Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age 18≤ Age ≤70. * BMI ≥ 28 kg/m². * The ASA classification ranges from I to II. * Patients have signed the informed consent form. * Patients undergoing gastroendoscopy and colonoscopy procedure. * The estimated duration of the procedure does not exceed 45 minutes.
Exclusion criteria
* Patients who exhibit contraindications to oropharyngeal airway ventilation, such as coagulation disorders, a predisposition to oral and nasal bleeding, mucosal damage, or anatomical constraints impeding oropharyngeal channel placement. * Severe cardiac insufficiency, defined as a maximal exercise capacity of less than 4 metabolic equivalents (METs). * Profound renal insufficiency necessitating preoperative dialysis. * A confirmed severe liver dysfunction. * Patients diagnosed with chronic obstructive pulmonary disease (COPD) or those presently experiencing other acute and chronic pulmonary conditions necessitating prolonged or intermittent oxygen therapy. * Elevated intracranial pressure. * Upper respiratory tract infections, encompassing the oral, nasal, and pharyngeal regions. * Fever, defined as a core body temperature exceeding 37.5 degrees Celsius. * Pregnancy or lactation. * Hypersensitivity reactions to sedatives like propofol or medical equipment such as adhesive tape. * Urgent surgical intervention. * Polytrauma. * Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively. * BMI\<28 kg/m². * Patients with a documented history of substance abuse, specifically drugs and/or alcohol, within the two years preceding the commencement of the screening period. Substance abuse in this context is defined as consuming more than three standard alcoholic beverages daily, roughly equivalent to 10g of alcohol or 50g of Chinese Baijiu. * Patients with a history of mental and neurological disorders, including but not limited to depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, and myasthenia gravis. * Presently engaged in concurrent participation in additional clinical trials. * Patients considered ineligible by researchers for inclusion in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of hypoxia | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | 75% ≤ SpO2 \< 90% for \<60 s |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of sub-clinical respiratory depression | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | 90% ≤ SpO2 \< 95% |
| SpO2 < 75% or 75% ≤ SpO2 < 90% for ≥60 s | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | SpO2 \< 75% or 75% ≤ SpO2 \< 90% for ≥60 s |
Other
| Measure | Time frame | Description |
|---|---|---|
| The incidence of other adverse events | Patients will be followed for the duration of hospital stay, an expected average about 2 hours | Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force |
Countries
China
Contacts
Primary ContactDiansan Su, Chief Physician
Backup ContactMingxia Xu
Outcome results
None listed